Associate Professor of Medicine, Johns Hopkins University
Cardiology
Dr. Paul A. Gurbel, MD
|
|
Give Review
Paul Gurbel practices Cardiology. He went to University of Maryland School of Medicine. University of Maryland School of Medicine has a rank of 37 in research and a 52 in primary care He received awards:"Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore", "Fellow (FACC)", "Super Doctor" and "Top MD". Doctor Paul A. Gurbel, MD has written publications. He has 99 publications published with PubMed. The lastest publication is: 'Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Antithrombotic therapy in medically managed patients with non-ST-segment elevation Acute coronary syndromes.
- Deciding about prolonged ticagrelor therapy in Coronary clot formers: an ongoing dilemma.
- Vorapaxar in the secondary prevention of atherothrombosis.
- G-protein-coupled receptors signaling pathways in new antiplatelet drug development.
- Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
- Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy.
- Resistance to antiplatelet drugs: what progress has been made?
- Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin.
- The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronar...
- Personalized antiplatelet therapy.
- Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?
- Statin therapy and thromboxane generation in patients with Coronary artery disease treated with high-dose aspirin.
- Antiplatelet and Anticoagulant Agents in Heart Failure: Current Status and Future Perspectives.
- Unraveling the Smokers' Paradox: Cigarette smoking, high-risk Coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors.
- Thrombin-induced platelet-fibrin clot strength: Relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous Coronary intervention outcomes.
- Pharmacology of antiplatelet agents.
- PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
- Importance of measurement of platelet reactivity to ADP in patients with Coronary artery disease: an historical account.
- The enigmatic search for optimal DAPT duration.
- Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous Coronary intervention.
- Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding.
- The next 10 years in personalized medicine in cardiology.
- Potential role of oral anticoagulants in the treatment of patients with Coronary artery disease: focus on dabigatran.
- P2Y12 Receptor Blockade and Myocardial Perfusion.
- Thienopyridine efficacy and cigarette smoking status.
- Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding.
- Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures.
- Cigarette smoking and clopidogrel interaction.
- The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study.
- Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with Coronary artery disease.
- Influence of CYP2C19*2 and *3 loss-of-function alleles on pharmacodynamic effects of standard- and high-dose clopidogrel in East Asians undergoing percutaneous coronar...
- Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated om...
- Genetic Variation in PEAR1 is Associated with Platelet Aggregation and Cardiovascular Outcomes.
- Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching anti-platelet (SWAP) study.
- Platelet reactivity and thrombogenicity in postmenopausal women.
- Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring.
- Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
- The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
- Importance of potent P2Y(12) receptor blockade in Acute myocardial infarction: focus on prasugrel.
- Translational platelet research in patients with Coronary artery disease: What are the major knowledge gaps?
- Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies.
- Clopidogrel efficacy and cigarette smoking status.
- Response to Letter Regarding Article, "Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coro...
- Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity.
- Platelet Function Measurement in Elective Percutaneous Coronary Intervention Patients: Exploring the Concept of a P2Y(12) Inhibitor Therapeutic Window.
- The role of platelet function testing and genotyping in the stented patient treated with clopidogrel.
- High platelet reactivity to multiple agonists during aspirin and clopidogrel treatment is indicative of a global hyperreactive platelet phenotype.
- Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with Acute coronary syndrome: A meta-analysis of randomized trials.
- Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With...
- Clinical efficacy and safety of intraCoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous Coronary intervention: A meta-...
- Cilostazol to Overcome High On-Treatment Platelet Reactivity in Korean Patients Treated With Clopidogrel and Calcium-Channel Blocker.
- Cutaneous clopidogrel hypersensitivity give steroids and do not stop the clopidogrel.
- "Sirolimus or paclitaxel drug eluting stent in left main Disease: The winner is??? "
- Time dependence of clopidogrel loading effect: Platelet activation versus platelet aggregation.
- Vorapaxar: a novel protease-activated receptor-1 inhibitor.
- Assessment of oral antithrombotic therapy by platelet function testing.
- We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity.
- Do East Asians have different hypercoagulable states compared with Western population?
- The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies.
- Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavo...
- Further ex vivo evidence supporting higher aspirin dosing in patients with Coronary artery disease and diabetes.
- Clopidogrel and proton pump inhibitors influence of pharmacological interactions on clinical outcomes and mechanistic explanations.
- An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial.
- The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
- Current options in oral antiplatelet strategies during percutaneous Coronary interventions.
- The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of ...
- The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
- First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genot...
- Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone.
- Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated ...
- Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
- Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events.
- Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
- Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocar...
- Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
- Delivery of glycoprotein IIb/IIIa inhibitor therapy for percutaneous Coronary intervention: why not take the intraCoronary highway?
- Combination antithrombotic therapies.
- Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable Coronary artery disease...
- The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular Disease on maintenance aspirin and clopidogrel therapy.
- The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous Coronary intervention patient.
- Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
- Expert consensus on treatment strategies in non- ST-segment elevation Acute coronary syndromes in patients undergoing percutaneous coronary intervention--an evidence-b...
- Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing Coronary arterial stenting.
- Response variability and the role of platelet function testing.
- Point-of-care platelet function analysis ready for prime time?
- Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to perip...
- Advances in antiplatelet therapy: agents in clinical development.
- Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with Coronary artery disease.
- Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study.
- The rationale for and comparisons of different antiplatelet treatments in Acute coronary syndrome.
- The association of cigarette smoking with enhanced platelet inhibition by clopidogrel.
- Treatment strategies in non-ST-elevation Acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial...
- Peri-procedural platelet function and platelet inhibition in percutaneous Coronary intervention.
- Omeprazole: a possible new candidate influencing the antiplatelet effect of clopidogrel.
- Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent Coronary artery disease: a...
- The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study.
- Platelet function monitoring in patients with Coronary artery disease.
- Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients.
Schools
University of Maryland At Baltimore Professional Schools
Duke University
Johns Hopkins
Procedures Preformed
- Ablation for Treatment of Cardiac Arrhythmias
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Ectasia
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
Awards
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Fellow (FACC)
- Super Doctor
- Top MD
Education
-
Duke University Hospital -
University of Maryland School of Medicine
Hospital
-
Inova Fairfax Hospital
Drug Facts
| NPI NUMBER | 1003888520 | |
| NPPES Provider LastName | GURBEL | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 212155216 | |
| NPPES Provider State | MD | |
| Specialty Description | Cardiology | |
| Total Claim Count | 553.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003888520 |
| Last Name Of The Provider | GURBEL |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. William L. Maughan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Momina I. Mastoor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael N. Rubinstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rinky Bhatia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian H. Kahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas Traill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Grant V. Chow, MD |
|
|
Dr. Gagandeep S. Gurm, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Herbert G. Oster, MD |
|
|
Dr. Armin A. Zadeh, MD |
|
|
Dr. Evan K. Grove, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jose D. Vargas, MD |